BG
ARQT icon

Bellevue Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Bellevue Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,008
Closed -$337K – 151
2025
Q2 		$337K Sell
24,008
-11,692
-33% -$164K 0.01% 113
2025
Q1 		$558K Sell
35,700
-3,800
-10% -$53.5K 0.01% 115
2024
Q4 		$550K Hold
39,500
– – 0.01% 124
2024
Q3 		$367K Buy
39,500
+22,000
+126% +$217K 0.01% 135
2024
Q2 		$163K Buy
+17,500
New +$158K ﹤0.01% 155

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group's ARQT Position: Q3 2025 in Review

Bellevue Group sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 24,008 shares — an estimated $337K sold.

Bellevue Group first reported a position in ARQT in Q2 2024 and held it in 5 quarters. The position peaked at $558K in Q1 2025. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Bellevue Group reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Bellevue Group sold 24,008 Arcutis Biotherapeutics shares in Q3 2025, an estimated $337K.
  • Bellevue Group first reported a position in Arcutis Biotherapeutics in Q2 2024 and held it in 5 quarters.
  • Bellevue Group's Arcutis Biotherapeutics position peaked at $558K in Q1 2025.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.